Literature DB >> 31168345

Therapeutic and protective effects of montelukast against doxorubicin-induced acute kidney damage in rats.

Evren Köse1, Fatih Oğuz2, Nigar Vardi3, Mehmet Ediz Sarihan4, Ali Beytur2, Aytaç Yücel5, Alaadin Polat6, Nihat Eki Nci7.   

Abstract

OBJECTIVES: The current study was designed to investigate the therapeutic and protective effects of montelukast (ML) against doxorubicin (DOX)-induced acute kidney damage in rats.
MATERIALS AND METHODS: Thirty-five Wistar albino female rats were randomly divided into 5 groups as follows: Group I: Control; Group II: Control+ML; Group III: DOX; Group IV: DOX+ML; Group V: ML+DOX. At the end of the experiment, the kidney tissues of rats were collected. Thiobarbituric acid reactive substance (TBARS), reduced glutathione, superoxide dismutase (SOD), and catalase levels were determined from the kidney tissues. In addition, the kidney tissues were examined histologically.
RESULTS: DOX induced a significant increase in the kidney TBARS levels, whereas SOD contents significantly decreased when compared with the control group. On the other hand, ML administration before and after DOX injection caused significant decreases in TBARS production and also increases in SOD levels. Histologically, the most remarkable damage was glomerulosclerosis and tubular changes in the DOX group. Moreover, marked tubular necrosis and swelling in tubular epithelial cells were observed in this group. Contrarily, although glomerulosclerosis was recognized as alleviated also in both DOX+ML and ML+DOX groups, the lesions did not completely ameliorate. However, treatment with ML after DOX injection was more effective than treatment with ML before DOX injection with respect to the protection of tubular structures.
CONCLUSION: It was determined that ML treatment after DOX injection caused therapeutic effects against DOX-induced kidney damage. Thence, ML treatment is of some clinical properties for oxidative stress damage in kidney tissues.

Entities:  

Keywords:  Doxorubicin; Histology; Kidney; Leukotrienes; Oxidative stress; TBARS

Year:  2019        PMID: 31168345      PMCID: PMC6535195          DOI: 10.22038/ijbms.2019.33493.7996

Source DB:  PubMed          Journal:  Iran J Basic Med Sci        ISSN: 2008-3866            Impact factor:   2.699


Introduction

Doxorubicin (DOX), an anthracycline antibiotic, has been used for the treatment of human neoplasms including leukemias, lymphomas, and solid tumors. The use of DOX is limited due to its side-effects; the most important are cardiotoxicity and nephrotoxicity (1-4). Though the toxicity of DOX on kidneys has not been clarified yet, it is believed that DOX-induced renal damage was caused by imbalanced oxidant-antioxidant systems (5, 6). Toxicity may be mediated through free radical formation, iron-dependent oxidative damage of biological macromolecules, membrane lipid peroxidation (LPO), and protein oxidation (7). The disturbance in oxidant-antioxidant systems, which has been demonstratedwith LPO and protein oxidation, results in tissue injury (8). Leukotrienes are a family of potent eicosanoid lipid mediators. They are synthesized from membrane phospholipids in response to cell activation. CysLTs (cysteinyl-leukotrienes) are produced from arachidonic acid through the 5-lipoxygenase (5-LO) pathway and act on the CysLT1 and CysLT2 receptors (9). A selective reversible CysLT1 receptor antagonist, montelukast (ML), is used in the treatment of asthma and reported to reduce eosinophilic inflammation in the airways (10-14). Sener et al. reported that bioactive metabolites of LTs had a pivotal role in the oxidative stress (15). Consistent with these important findings, we previously reported that ML had significant antioxidant properties against methotrexate-induced renal and liver damages (16, 17). To our knowledge, there has been no research regarding the protective and therapeutic effects of ML against DOX-induced acute kidney toxicity. Therefore, the current study was designed to investigate the therapeutic and protective effects of ML against DOX-induced acute kidney damage in rats.

Materials and Methods

Forty Wistar albino female rats were housed in an air-conditioned room with 12 hr light and dark cycles, where the temperature (22±2 °C) and relative humidity (65–70%) were kept constant. All experimental protocols were approved by the Experimental Animals Ethical Committee, School of Medicine, Inonu University, Malatya, Turkey. The rats were randomly divided into 5 groups as follows: Group I: Control; Group II: ML (Notta tb® 10 mg, Sanovel, Turkey, 10 mg/kg daily for 10 days PO); Group III: DOX (Doxorubicin® 50 mg, Farmar, Turkey, single dose 20 mg/kg IP); Group IV: DOX (single dose 20 mg/kg IP.)+ML (10 mg/kg daily for 10 days PO, 3 days after DOX injection); Group V: ML (10 mg/kg daily for 10 days PO)+DOX (single dose 20 mg/kg IP after the last dose of ML). On the 14th day, the rats in all groups were killed and the kidney tissues of rats were collected. The kidney tissues were placed into liquid nitrogen and stored at –70 °C until assayed for thiobarbituric acid reactive substance (TBARS), reduced glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT). The other kidney tissues were fixed at 10% formalin for histopathological analyses. The levels of homogenized tissue TBARS, as an index of lipid peroxidation, were determined by thiobarbituric acid reaction using the method of Yagi (18). The product was evaluated spectrophotometrically at 532 nm, and the results were expressed as nmol/g tissue. The GSH content of the testis homogenate was measured at 412 nm using a known method (19). The GSH level was expressed as nmol/ml. Superoxide dismutase (SOD) activity was measured by the inhibition of nitroblue tetrazolium (NBT) reduction due to O2 generated by the xanthine/xanthine oxidase system (20). One unit of SOD activity was defined as the amount of protein causing 50% inhibition of the NBT reduction rate. The product was evaluated spectrophotometrically at 560 nm. The results were expressed as U/mg protein. CAT activity of tissues was determined in accordance with the method explained by Aebi (21). The enzymatic decomposition of H2O2 was followed directly by the decrease in absorbance at 240 nm. The difference in absorbance per unit time was used as a measure of CAT activity. The enzyme activities were given in kU/mg protein. The kidneys were fixed in 10% formalin, embedded in paraffin blocks, and sectioned. The sections of renal tissue were stained with hematoxylin-eosin (H-E) and periodic acid-Schiff (PAS) and examined by light microscopy in a blinded fashion. A semiquantitative morphometric score index was used to evaluate the degree of glomerulosclerosis. Sclerosis was defined as obliteration of glomerular capillary tuft and decrease of Bowman’s space. Glomerulosclerosis scoring was performed by taking the severity and extent of the sclerotic lesion into consideration for each glomerulus. Thus, each glomerulus was assigned a score between 0 and 4 in the following way: 0 for normal glomeruli, 1 for sclerosis in ≤25% of the total area; 2 for sclerosis in 25%–50% of the total area; 3 for sclerosis in 50%–75% of the total area; and 4 for sclerosis in ≥80% of the total area. This analysis method of glomerulus was modified from Fujihara et al. (22). One hundred glomeruli were evaluated in each kidney, and the arithmetic mean of the sclerosis scores was accepted as the mean glomerulosclerosis score (MGS) for that rat. Tubular injury was defined as tubular necrosis, desquamation, tubular epithelial cell swelling, and loss of the brush border. The following semiquantitative score was used: score 0=no tubular injury; score 1= 0–25% of the tubules were injured; score 2=25–50% of the tubules were injured; score 3=50–75% of the tubules injured; and score 4 = >75% of the tubules were injured. For each specimen, 10 microscopic fields were analyzed under a 20X objective per animal. The sections were examined using a Leica DFC 280 light microscope. The data were expressed as either median (min-max) value. Normality distribution was assessed using the Shapiro-Wilk test. The non-normally distributed data were compared by the Kruskal Wallis H test between the groups. When significant differences were determined, multiple comparisons were carried out using the Mann Whitney U test with Bonferroni correction. P<0.05 values were considered as significant. IBM SPSS statistics version 25.0 for Windows was used for statistical analyses.

Results

The kidney TBARS, GSH, SOD, and CAT levels for ML and DOX-treated rats were presented in Table 1. It was determined that DOX induced a significant increase in the kidney TBARS levels, whereas SOD contents significantly decreased when compared with the control group (P<0.05). On the other hand, ML administration before and after DOX injection caused significant decreases in TBARS production and also increases in SOD levels (P<0.05). There were no statistically significant differences for GSH and CAT levels. On the other hand, the levels of GSH and CAT of the DOX-ML group were higher than those of the ML-DOX group.
Table 1

The levels of biochemical parameters of all groups

Parameters Control ML DOX ML-DOX DOX-ML
MDA197,1 (107,1-222,7)236,5 (104,9-250,1)255,6 (194,3-308,2)a159,8 (105,7-267,1)143,2 (119,6-185,9)
SOD0,396(0,35-0,47)0,395 (0,35-0,51)0,269 (0,21-0,4) b0,415 (0,29-0,55)0,51 (0,31-0,64)
CAT377,25±34,29364,91±34,29301,17±102,16330,21±93,87403,57±87,20
GSH2,26±0,272,58±0,362,33±0,461,67±0,262,49±02,99

Significantly increased compared with control, ML-DOX, and DOX-ML

Significantly decreased compared with other groups

Control group (a) Renal glomeruli and (b) tubules are intact. (c) Brush border is visible. (a) and (c) PAS X40, (b)H-E X20 PAS: periodic acid-Schiff, H-E: hematoxylin-eosin DOX group (a) Obliteration of glomerular capillary tuft and presence of glomerular tuft capsular adhesion compared to the control group can be observed in the glomerulus (b) tubules show marked necrosis (*) and swelling in tubular epithelial cells (arrows) (c) notice lost brush border. (a) and (c) PAS X40, (b) H-E X20 DOX: Doxorubicin, PAS: periodic acid-Schiff, H-E: hematoxylin-eosin DOX+ML and ML+DOX groups (a) and (d) there is a prominent reduction in the degree of glomerulosclerosis according to the DOX group. Bowman’s space is visible (b) and (e) moderate tubular damage such as desquamation of tubular epithelial cells are observed. (c) the view of brush border is almost similar to the control group (f) the loss of brush border is marked in affected tubules. (a,d) and (c,f) PASX40, (b,e) H-E X20 DOX: Doxorubicin, ML: montelukast, PAS: periodic acid-Schiff, H-E: hematoxylin-eosin The levels of biochemical parameters of all groups Significantly increased compared with control, ML-DOX, and DOX-ML Significantly decreased compared with other groups The comparison of severity of glomerulosclerosis among groups Significantly decreased when compared with the control group, P =0.00. Significantly increased when compared with the control group, P =0.00. Significantly increased when compared with the DOX group, P =0.00. Significantly decreased when compared with the DOX group, P =0.00. Not significant when compared with the DOX-ML group, P =0.6. Significantly decreased when compared with the DOX-ML group, P =0.00. The comparison of severity of renal tubular injury between groups Significantly increased when compared with the control group, P =0.01. Significantly decreased when compared with the DOX group, P =0.005. The control group showed normal or slight changes such as epithelial desquamation. Glomeruli and brush border were observed as intact (Figures 1a, 1b, and 1c). The ML group exhibited similar morphological changes as observed in the control group. The most remarkable damage was glomerulosclerosis and tubular changes in the DOX group. Glomeruli revealed obliteration of glomerular capillary tuft and presence of glomerular tuft capsular adhesion (Figure 2a). Moreover, marked tubular necrosis and swelling in tubular epithelial cells were observed in this group (Figure 2b). The widespread loss of the brush border was observed in the affected tubules (Figure 2c). On the other hand, although glomerulosclerosis was recognized as alleviated also in both DOX+ML and ML+DOX groups, the lesions did not completely ameliorate. (Figures 3a and 3d). The appearance of glomeruli was similar in these groups. However, treatment with ML after DOX injection was more effective than treatment with ML before DOX injection with respect to the protection of tubular structures (Figures 3b and 3e). But, no difference was found significant statistically between the two groups in terms of tubular injury (P>0.05). Brush border was relatively intact in the DOX+ML group according to the ML+DOX group (Figures 3c and 3f). Using semiquantitative scoring methods, the mean values of the glomerulosclerosis and tubular damage were determined and given in Tables 2 and 3.
Figure 1

Control group

Figure 2

DOX group

Figure 3

DOX+ML and ML+DOX groups

Table 2

The comparison of severity of glomerulosclerosis among groups

Mean glomerulosclerosis score
Groups 01234
Control95.9±0.54.1±0.50.0±0.00.0±0.00.0±0.0
ML99.3±0.20.6±0.20.0±0.00.0±0.00.0±0.0
DOX0.0±0.0a2.1±0.37.3±0.3b45.1±0.8b45.37±0.6b
DOX-ML10.0±0.1a,c 40.1±0.4b,c33.6±0.6b,c13.2±0.7b,d3.0±0.2d
ML-DOX18.0±0.2a,c32.6±0.7b,c,f32.±0.6b,c,e17.37±0.7b,d0.0±0.0 d,f

Significantly decreased when compared with the control group, P =0.00.

Significantly increased when compared with the control group, P =0.00.

Significantly increased when compared with the DOX group, P =0.00.

Significantly decreased when compared with the DOX group, P =0.00.

Not significant when compared with the DOX-ML group, P =0.6.

Significantly decreased when compared with the DOX-ML group, P =0.00.

Table 3

The comparison of severity of renal tubular injury between groups

Groups Tubular Injury
Control0.4±0.2
ML0.5±0.2
DOX3.2±0.3a
DOX-MLML-DOX1.6±0.6a,b2.4± 0.2a

Significantly increased when compared with the control group, P =0.01.

Significantly decreased when compared with the DOX group, P =0.005.

Discussion

In the current research, the potentially harmful effects of DOX on the kidneys were examined biochemically and histologically. DOX is used as a chemotherapeutic agent in various leukemias and lymphomas (1). Despite its beneficial effects, DOX has considerable cardiotoxic and nephrotoxic harmful effects (2, 3, 23). DOX-induced cardiotoxicity and nephrotoxicity have been investigated in many biomedical studies. It is reported that the use of DOX results in increased production of free radicals that react rapidly with lipids causing Lipid peroxidation (LPO) (24). Increased LPO is measured in terms of TBARS levels. In the present research, DOX-treated rats showed an increased level of TBARS and a decreased level of SOD compared to control rats. TBARS, a stable metabolite of the free radical-mediated lipid peroxidation cascade, is used widely as a marker of oxidative stress and lipid layer destruction (25). Elevated TBARS levels show that DOX has caused oxidative stress and the formation of free radicals in the kidney tissue. SOD has a significant role against oxidative damage caused by free radicals (26) and converts superoxide ion (O2-) to hydrogen peroxide (H2O2). A clinical study examined the effects of nicotinamide against nephrotoxicity induced by DOX and reported that antioxidant and anti-inflammatory properties of NAD could decrease the nephrotoxicity induced by DOX (27). In accordance with the mentioned study (27), experimental findings of this study have indicated that the therapeutic and protective effects of ML administration can impair DOX-induced acute renal damages in rats. This important inference from the experiments has been confirmed based on histological and biochemical findings of the treatment of ML. Another objective of the current research was to investigate the possible therapeutic and protective effects of ML against DOX-induced acute kidney damage in rats. ML is employed to treat asthma and to alleviate the symptoms of seasonal allergies and can decrease eosinophilic inflammation in the respiratory tract (28). In this study, ML treatment before and after DOX injection prevented possible oxidative stress damage in kidney tissues. These important findings were achieved from the biochemical data owing to the significant decreases of TBARS production and the significant increases of SOD levels. According to the histological results, renal damage decreased in a similar way to the biochemical results. The treatment with ML after DOX injection in the reduction of tubular injury was more successful as compared with the treatment with ML before DOX injection. In a clinical trial similar to our hypothesis, the potential protective effect of ML on renal ischemia/reperfusion (I/R) damage was evaluated and was concluded that ML maintained renal tissue by improving oxidant–antioxidant balance, which was proved with biochemical and histopathological findings (10). Another experimental research examined the probable protective effect of ML towards oxidative damage in kidney tissues and indicated that ML is capable of protecting kidney tissues from oxidative damage (29). In our previous study, we designed a different experimental model investigating the protective and therapeutic effects of ML against amikacin-induced acute kidney injury. We showed that ML administration after amikacin injection decreased the oxidative injury (28). With respect to DOX administration, a recent study has dealt with the current schemes for primary and secondary prevention targeting by contrasting the commencement of early and late DOX-induced cardiotoxic events (2). Additionally, the protective effects of dioscin were administrated on the DOX-induced nephrotoxicity by correcting FXR-mediated inflammation and oxidative stress (4). In this respect, DOX-induced applications in biomedical studies keep up to date from the clinical point of view.

Conclusion

It was determined that ML treatment after DOX injection caused therapeutic effects against DOX-induced kidney damage. Thence, ML treatment has some clinical applications for oxidative stress damage in kidney tissues.
  27 in total

1.  Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist.

Authors:  Halil Tuğtepe; Göksel Sener; Sule Cetinel; Ayliz Velioğlu-Oğünç; Berrak C Yeğen
Journal:  Eur J Pharmacol       Date:  2006-11-10       Impact factor: 4.432

2.  The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats.

Authors:  S Y Saad; T A Najjar; A C Al-Rikabi
Journal:  Pharmacol Res       Date:  2001-03       Impact factor: 7.658

3.  Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats.

Authors:  Li-Lin Liu; Qi-Xiong Li; Lin Xia; Jing Li; Lang Shao
Journal:  Toxicology       Date:  2006-12-01       Impact factor: 4.221

4.  Montelukast protects against renal ischemia/reperfusion injury in rats.

Authors:  Göksel Sener; Ozer Sehirli; Ayliz Velioğlu-Oğünç; Sule Cetinel; Nursal Gedik; Metin Caner; Abdullah Sakarcan; Berrak C Yeğen
Journal:  Pharmacol Res       Date:  2006-03-02       Impact factor: 7.658

5.  Effects of melatonin in reducing the toxic effects of doxorubicin.

Authors:  Eser Oz; Mustafa N Ilhan
Journal:  Mol Cell Biochem       Date:  2006-04-20       Impact factor: 3.396

6.  The protective effect of montelukast sodium on carbon tetrachloride induced hepatopathy in rat.

Authors:  Magdalena Cuciureanu; Irina-Draga Căruntu; Ofelia Păduraru; Bogdan Stoica; Luminita Jerca; Eduard Crauciuc; Mihai Nechifor
Journal:  Prostaglandins Other Lipid Mediat       Date:  2008-11-11       Impact factor: 3.072

7.  Chronic renal failure-induced multiple-organ injury in rats is alleviated by the selective CysLT1 receptor antagonist montelukast.

Authors:  Göksel Sener; Abdullah Sakarcan; Ozer Sehirli; Emel Ekşioğlu-Demiralp; Emre Sener; Feriha Ercan; Nursal Gedik; Berrak C Yeğen
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-01-20       Impact factor: 3.072

8.  Effects of pentoxifylline in adriamycin-induced renal disease in rats.

Authors:  Yusuf Usta; Ugur Burcin Ismailoglu; Aysin Bakkaloglu; Dicle Orhan; Nesrin Besbas; Inci Sahin-Erdemli; Seza Ozen
Journal:  Pediatr Nephrol       Date:  2004-06-16       Impact factor: 3.714

9.  Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats.

Authors:  Ersin Fadillioğlu; Hasan Erdoğan; Sadik Söğüt; Irfan Kuku
Journal:  J Appl Toxicol       Date:  2003 Jan-Feb       Impact factor: 3.446

10.  Protective effects of leflunomide against ischemia-reperfusion injury of the rat liver.

Authors:  Abdurrahman Karaman; Ersin Fadillioglu; Emine Turkmen; Erkan Tas; Zumrut Yilmaz
Journal:  Pediatr Surg Int       Date:  2006-03-24       Impact factor: 1.827

View more
  5 in total

1.  Synergistic impacts of Montelukast and Klotho against doxorubicin-induced cardiac toxicity in Rats.

Authors:  Heba A Elnoury; Salwa A Elgendy; Samar H Baloza; Heba I Ghamry; Mohamed Soliman; Eman Abdel-Mohsen Abdel-Aziz
Journal:  Toxicol Res (Camb)       Date:  2022-06-20       Impact factor: 2.680

2.  Anti-Inflammatory, Anti-Apoptotic, and Antioxidant Roles of Honey, Royal Jelly, and Propolis in Suppressing Nephrotoxicity Induced by Doxorubicin in Male Albino Rats.

Authors:  Hanaa K Mohamed; Maysa A Mobasher; Rasha A Ebiya; Marwa T Hassen; Howaida M Hagag; Radwa El-Sayed; Shaimaa Abdel-Ghany; Manal M Said; Nabil S Awad
Journal:  Antioxidants (Basel)       Date:  2022-05-23

Review 3.  Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Yaaser Q Almulaiky; Natália Cruz-Martins; Gaber El-Saber Batiha
Journal:  Eur J Pharmacol       Date:  2021-05-15       Impact factor: 4.432

4.  Interference with megalin expression/endocytic function by montelukast mitigates gentamicin nephrotoxicity: Downregulation of ClC-5 expression.

Authors:  Amany A Azouz; Dina A Hanna; Ali A Abo-Saif; Basim Anwar Shehata Messiha
Journal:  Saudi Pharm J       Date:  2022-01-04       Impact factor: 4.562

5.  Leukotriene Receptor Antagonist, Montelukast Ameliorates L-NAME-Induced Pre-eclampsia in Rats through Suppressing the IL-6/Jak2/STAT3 Signaling Pathway.

Authors:  Walaa Yehia Abdelzaher; Gomaa Mostafa-Hedeab; Haitham Ahmed Bahaa; Ahmad Mahran; Michael Atef Fawzy; Sara Mohamed Naguib Abdel Hafez; Nermeen N Welson; Remon Roshdy Rofaeil
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.